Longevity TV

Defining biological aging

Longevity TV

Towards a consensus definition of biological aging

Phil Newman - 0
Attila Csordas, Founder & Director, AgeCurve Ltd.
Read more
Longevity TV

Reversal of several aging pathways & diseases

Phil Newman - 0
George Church, Founding Core Faculty & Lead, Synthetic Biology, Wyss Institute at Harvard University.
Read more
Longevity TV

Leveraging aging science (geroscience) to improve older adults’ immune health

Phil Newman - 0
Nir Barzilai, Director, Institute for Aging Research.
Read more
Longevity TV

Connections & differences between different hallmark processes

Phil Newman - 0
Lynne Cox, Associate Professor in Biochemistry, University of Oxford.
Read more
More from 'Defining biological aging'

Rejuvenation therapies

Longevity TV

The divide-and-conquer nature of rejuvenation can be an asset, not a challenge

Phil Newman - 0
Aubrey de Grey, Founder and CEO, SENS Foundation.
Read more
Longevity 2020

The use of TORC1 inhibitors to improve immune function in the elderly

Phil Newman - 0
Joan Mannick, Chief Medical Officer, resTORbio
Read more
Longevity TV

How do we show in humans that a drug targets aging?

Phil Newman - 0
Nir Barzilai, Director, Institute for Aging Research
Read more
Longevity TV

Geroprotectors: time to change the way we treat older people?

Phil Newman - 0
Ilaria Bellantuono, Professor in Musculoskeletal Ageing, Co-Director, The Healthy Lifespan Institute, Department of Oncology and Metabolism
Read more
More from 'Rejuvenation therapies'

AI & Longevity

Longevity TV

Extending healthspan with NaNot nano-extractors

Phil Newman - 0
Lou Hawthorne, CEO, NaNotics
Read more
Longevity TV

Interview with Margaretta Colangelo

Phil Newman - 0
Margaretta Colangelo, Co-founder / Managing Partner, Deep Knowledge Ventures / Longevity.Capital / Deep Knowledge Analytics
Read more
Longevity TV

Applying AI approaches to diverse aging-related problems

Phil Newman - 0
Alexander Zhavoronkov, Chief Executive Officer, Insilico Medicine, Inc
Read more
Longevity TV

Margaretta Colangelo in conversation with Richard Siow, John Shepherd, and Alexander Zhavoronkov

Phil Newman - 0
Margaretta Colangelo, Co-founder / Managing Partner, Deep Knowledge Ventures / Longevity.Capital / Deep Knowledge Analytics
Read more
More from 'AI & Longevity'

Longevity investing

Longevity TV

The Big Picture: Covid-19 and Longevity investing

Phil Newman - 0
Jim Mellon, Chairman and Founder, Burnbrae Group
Read more
Longevity TV

The view from the valley

Phil Newman - 0
Kate Batz, Managing Partner, Longevity Capital and Director of Strategy at Deep Knowledge Ventures and Aging Analytics Agency.
Read more
Longevity TV

Accelerating agetech

Phil Newman - 0
Lorraine Morley, UK Lead / Advisor, AgeTech Accelerator
Read more
Longevity TV

The Juvenescence business model and future of anti-aging

Phil Newman - 0
Greg Bailey, CEO, Juvenescence
Read more
More from 'Longevity investing'

Longevity start now

Longevity TV

Longevity: Start now … Introduction

Phil Newman - 0
Johnny Adams, CEO / Executive Director, Aging Intervention Foundation; Executive Director, Gerontology Research Group
Read more
Longevity TV

Early access to the treatment of aging: distinguishing rational self-experimentation from arrant foolishness

Phil Newman - 0
Reason, Co-founder and CEO, Repair Biotechnologies & Fight Aging!
Read more
Longevity TV

Rejuvant – starting Longevity now

Phil Newman - 0
Tom Weldon, Founder, Executive Chairman, Acting CEO, Ponce De Leon Health
Read more
Longevity TV

How can BioViva address the here and now?

Phil Newman - 0
Liz Parrish, CEO, BioViva Sciences
Read more
More from 'Longevity start now'

Latest articles

Fountain’s ‘hypothesis-free’ approach to Longevity AI

Development Danny Sullivan - 0
We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...
Read more

G3 and Juvenescence partner on deep learning venture

Development Eleanor Garth - 0
G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...
Read more

Building an artificial immune system

Diagnostic Tools Danny Sullivan - 0
DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...
Read more

Neurotech is the new blue ocean

Longevity TV Eleanor Garth - 0
Alon Braun, Co-Founder, Neurotech Analytics.
Read more
TISSUE/ORGAN | NANOTECH | SENESCENCE | CELLULAR | DRUGS | AI | NEURAL | AGETECH | INVESTMENT

LONGEVITY MARKET | ABOUT US | MY ACCOUNT | SHARE YOUR NEWS | CONTACT US

PRIVACY POLICY | COOKIE POLICY | TERMS AND CONDITIONS | COPYRIGHT POLICY

© Copyright 2020 PERGALI Limited. All rights reserved. PERGALI, Longevity.Technology and their associated logos are trademarks of PERGALI Limited and are the subject of trademark applications or registrations in various countries around the world. All other trademarks are the property of their respective owners. All PERGALI products and services are subject to continuous development. We reserve the right to alter technical specifications without prior notice.